EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Lung cancer is the leading cause of cancer incidence and mortality, with an estimated 2 million diagnosed cases and 1.8 million deaths per year reported worldwide [1]. In 2022, an estimated 0.87 million new cases and 0.76 million deaths of lung cancer were reported in China [2]. Non –small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85 % of all cases [3–5]. Over the past decade, advances in our understanding of cell signaling pathways that control cell survival have identified genetic and epigenetic alterations, which promote cell prolif eration and tumorigenesis. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 6, 2023 Category: Cancer & Oncology Authors: Qianming Bai, Jialei Wang, Xiaoyan Zhou Tags: Anti-tumour Treatment Source Type: research
EGFR exon20 insertion mutations in non –small cell lung cancer: Clinical implications and recent advances in targeted therapies
Lung cancer is the leading cause of cancer incidence and mortality, with an estimated 2 million diagnosed cases and 1.8 million deaths per year reported worldwide [1]. In 2022, an estimated 0.87 million new cases and 0.76 million deaths of lung cancer were reported in China [2]. Non –small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cases [3–5]. Over the past decade, advances in our understanding of cell signaling pathways that control cell survival have identified genetic and epigenetic alterations, which promote cell prolifer ation and tumorigenesis. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 6, 2023 Category: Cancer & Oncology Authors: Qianming Bai, Jialei Wang, Xiaoyan Zhou Tags: Anti-tumour Treatment Source Type: research
Expert Consensus Guidelines for the Prophylaxis and Management of Tumor Lysis Syndrome in the United States: Results of a Modified Delphi Panel
Tumor lysis syndrome (TLS), which occurs spontaneously or in response to anticancer treatment, results in the release of intracellular potassium, phosphorus, and nucleic acids into the bloodstream, which results in secondary clinical complications that may be fatal. Prior TLS guidelines do not take into consideration potent novel oncologic agents or contemporary treatment paradigms with increased risk of TLS. Thus, a modified Delphi panel of experts was convened to provide an update for TLS management guidelines based upon a combination of supporting literature and practice consensus. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 5, 2023 Category: Cancer & Oncology Authors: Anthony J. Perissinotti, Michael R. Bishop, Joseph Bubalo, Mark B. Geyer, Amy Goodrich, Scott C. Howard, Julianna Kula, Sreedhar Mandayam, Mitchell S. Cairo, Ching-Hon Pui Tags: Anti-tumour Treatment Source Type: research
Liquid Biopsy After Resection Of Pancreatic Adenocarcinoma And Its Relation To Oncological Outcomes. Systematic Review And Meta-Analysis
Pancreatic ductal adenocarcinoma (PDAC) is the seventh cause of cancer-related death worldwide and third place in Europe [1,2]. The actual 5-year survival rate is 12% [3]. This low survival rate is mainly due to late diagnosis, aggressive biology and resistance to current chemotherapy regimens [4 –7]. Only 20% are resectable at diagnosis; despite surgical resection, approximately 80% recurred. Furthermore, several factors may contribute to the recurrence of PDAC after resection, such as R1 status ( (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 5, 2023 Category: Cancer & Oncology Authors: Laura Vidal, Elizabeth Pando, Laia Blanco, Carles Fabregat – Franco, Florian Castet, Alexandre Sierra, Teresa Macarulla, Joaquim Balsells, Ramón Charco, Ana Vivancos Tags: Systematic or Meta-analysis Studies Source Type: research
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: a systematic review
Immune checkpoint inhibitors (ICIs), namely anti- programmed cell death 1 (anti-PD-1), anti- programmed death ligand 1 (anti-PD-L1) and anti- cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), have entered clinical practice for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy, warranting long-term survival in a certain proportion of patients [1 –5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 18, 2023 Category: Cancer & Oncology Authors: Ilaria Attili, Antonio Passaro, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Filippo de Marinis Tags: Anti-tumour Treatment Source Type: research
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: a systematic review and meta-analysis of phase 3 randomized controlled trials
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized cancer treatment in recent years [1]. Indeed, many PARPi have already been granted regulatory approvals, either as monotherapy or in combination with other agents, and consequently reached clinical practice, in the treatment of several solid tumors like ovarian, breast, pancreatic and prostate cancers [2 –5]. PARPi target the DNA damage response pathway, which plays a crucial role in maintaining genomic stability. Specifically, PARP enzymes are critical for repairing single-strand DNA breaks, which occur frequently during DNA replication. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 15, 2023 Category: Cancer & Oncology Authors: Grazia Castellano, Chiara Corti, Laura Boldrini, Lorenzo Gervaso, Carmen Criscitiello, Giuseppe Curigliano Tags: Anti-tumour Treatment Source Type: research
Review: Targeting EZH2 in Neuroblastoma
Neuroblastoma is the most common extra-cranial solid tumor with up to 100 children newly diagnosed annually in the UK [1]. Around 40% of patients are diagnosed before 1 year old and the median age at diagnosis is 17-18 months [2]. Neuroblastoma is an embryonal tumor of the sympathetic nervous system arising from immature neural crest cells [3]. It generally originates in the adrenal glands (65%), however, it can arise from anywhere containing sympathetic nervous tissue, including the chest (20%), neck (5%) and pelvis (5%) [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 12, 2023 Category: Cancer & Oncology Authors: Jinhui Gao, Claire Fosbrook, Jane Gibson, Timothy Underwood, Juliet Gray, Zo ë Walters Tags: Anti-tumour Treatment Source Type: research
The immunogram of inflammatory breast cancer
Inflammatory breast cancer (IBC) is the most aggressive clinical presentation of breast cancer (BC) and accounts for 2-4% of all new cases [1]. The treatment of non-metastatic IBC includes standard neoadjuvant therapy, surgery and radiotherapy. Instead, patients with metastatic IBC are treated with systemic therapy regimens not dissimilar to the treatments used for non-IBC[2]. The improvement of median overall survival (OS) of patients with localized IBC, to nearly 4 years with multimodality treatment, is still unsatisfying and tremendous efforts are required to improve the poor outcomes of this fatal form of BC [3]. (Sour...
Source: Cancer Treatment Reviews - July 7, 2023 Category: Cancer & Oncology Authors: Carmine Valenza, Dario Trapani, Nicola Fusco, Xiaoping Wang, Massimo Cristofanilli, Naoto T. Ueno, Giuseppe Curigliano Tags: Anti-tumour Treatment Source Type: research
Uveal melanoma: in the era of new treatments
Uveal Melanoma (UM), also called choroidal melanoma, is a rare and poorly described disease that occurred in 3490 new cases in the United States in 2023 [1 –2]. It is the most common primary intraocular malignancy in adults. Although 5-year survival is relatively high at the localized and regional stages, 85% and 67% respectively, the challenge of managing this disease lies primarily in the metastatic stage where survival rates drop to only 16% [3]. The incidence of UM has been constant since the last few years. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 7, 2023 Category: Cancer & Oncology Authors: M. Wespiser, E. Neidhardt, S. Negrier Tags: Anti-tumour Treatment Source Type: research
Current Indications and Future Perspectives for Antibody-Drug Conjugates in Brain Metastases of Breast Cancer
Breast cancer is one of the main cause of cerebral and leptomeningeal metastases, the prognosis of which remains poor to this day. Most studies excluded patients with active brain metastases (BM) and particularly with leptomeningeal metastases (LM) explaining the lack of therapeutic innovation in this area. Currently, the standard management of patients with BM of breast cancer is based on the combination of surgery, radiotherapy and systemic treatments. Recently, third-generation of Antibody-Drug Conjugates (ADCs), have revolutionized the management of metastatic breast cancer. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 6, 2023 Category: Cancer & Oncology Authors: N. Epaillard, J. Bassil, B. Pistilli Tags: Anti-tumour Treatment Source Type: research
Corrigendum to “Clinical trial designs for evaluating and exploiting cancer evolution” [Cancer Treat. Rev. 118 (2023) 101583]
The authors regret that important information was omitted from the Acknowledgments and Funding sections of the above-mentioned article. The text in these sections should read as follows: (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 5, 2023 Category: Cancer & Oncology Authors: Alvaro H. Ingles Garces, Nuria Porta, Trevor A. Graham, Udai Banerji Tags: Corrigendum Source Type: research
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511]
The authors regret that the institution address given with affiliation b in the published article was incomplete. The correct affiliation in full is updated as above. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 1, 2023 Category: Cancer & Oncology Authors: F. Miglietta, A. Fabi, D. Generali, M.V. Dieci, G. Arpino, G. Bianchini, S. Cinieri, P.F. Conte, G. Curigliano, M. De Laurentiis, L. Del Mastro, S. De Placido, A. Gennari, F. Puglisi, A. Zambelli, F. Perrone, V. Guarneri Tags: Corrigendum Source Type: research
Strategies for improving detection of circulating tumor DNA using Next Generation Sequencing
1. Introduction (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 23, 2023 Category: Cancer & Oncology Authors: T ébar-Martínez Roberto, Martín-Arana Jorge, Gimeno-Valiente Francisco, Tarazona Noelia, Rentero-Garrido Pilar, Cervantes Andrés Tags: Laboratory-Clinic Interface Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 21, 2023 Category: Cancer & Oncology Source Type: research
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: a systematic review and meta-analysis
The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) represent the current standard of care as first- or second-line treatment for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, demonstrating improved survival outcomes compared to endocrine therapy (ET) alone [1 –3]. Moreover, both abemaciclib and ribociclib, when combined with ET, have demonstrated a significant improvement in invasive disease-free survival in patients with HR+/HER2- early breast cancer who are at high risk of recurrence [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 15, 2023 Category: Cancer & Oncology Authors: Carlotta Becherini, Luca Visani, Saverio Caini, Indrani S. Bhattacharya, Anna M. Kirby, Gustavo Nader Marta, Gilberto Morgan, Viola Salvestrini, Charlotte E. Coles, Javier Cortes, Giuseppe Curigliano, Evandro de Azambuja, Nadia Harbeck, Clare M. Isacke, O Tags: Systematic or Meta-analysis Studies Source Type: research
